Objective The aim of this study was to compare the usefulness of cefoperazone-sulbactam
and that of piperacillin-tazobactam in the treatment of hospital-acquired pneumonia (HAP)
and ventilator-associated pneumonia (VAP). Methods This retrospective study included the
adult patients receiving cefoperazone-sulbactam or piperacillin-tazobactam against
HAP/VAP in nine hospitals in Taiwan from March 1, 2018 to May 30, 2019. Primary outcome
was clinical cure rate. Results A total of 410 patients were enrolled. Among them, 209 …

The objective was to compare the clinical efficacy of cefoperazone-sulbactam with
piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP).
The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical
outcomes were compared for patients who received either cefoperazone-sulbactam or
piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were
enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin …